Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
Glioblastomas that have an "unmethylated" MGMT gene are less likely to respond to the standard chemotherapy drug temozolomide. In this study, researchers are comparing three investigational treatments (abemaciclib, CC-115, and neratinib) with the standard treatment (temozolomide and radiation therapy) in patients newly diagnosed with glioblastoma.
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
Researchers are comparing different treatments for triple-negative breast cancer (TNBC). The people in this study have TNBC that has been surgically removed.
Researchers want to find the best dose of BDTX-4933 to use in people with advanced lung cancer. The people in this study have non-small cell lung cancer that has a mutation (change or variant) in the BRAF or KRAS genes (KRAS non-G12C mutation). This mutation can cause cancer cells to grow.
Researchers are assessing the combination of BNT326 and BNT327 in people with advanced lung cancer that has spread. The people in this study have non-small cell lung cancer (NSCLC) that came back or keeps growing after treatment.
Researchers want to find the best doses of BNT323 and BNT327 to treat breast cancer. The people in this study have breast cancer that has spread and keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
